215 related articles for article (PubMed ID: 9393871)
1. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
[TBL] [Abstract][Full Text] [Related]
2. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
3. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
4. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
6. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
7. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
Asai N; Murakami H; Iwashita T; Takahashi M
J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
[TBL] [Abstract][Full Text] [Related]
8. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
9. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
10. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
[TBL] [Abstract][Full Text] [Related]
11. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
[TBL] [Abstract][Full Text] [Related]
13. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.
Lorenzo MJ; Gish GD; Houghton C; Stonehouse TJ; Pawson T; Ponder BA; Smith DP
Oncogene; 1997 Feb; 14(7):763-71. PubMed ID: 9047383
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
15. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.
Pelicci G; Troglio F; Bodini A; Melillo RM; Pettirossi V; Coda L; De Giuseppe A; Santoro M; Pelicci PG
Mol Cell Biol; 2002 Oct; 22(20):7351-63. PubMed ID: 12242309
[TBL] [Abstract][Full Text] [Related]
16. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
17. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
18. Role of Dok1 in cell signaling mediated by RET tyrosine kinase.
Murakami H; Yamamura Y; Shimono Y; Kawai K; Kurokawa K; Takahashi M
J Biol Chem; 2002 Sep; 277(36):32781-90. PubMed ID: 12087092
[TBL] [Abstract][Full Text] [Related]
19. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
20. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]